CL2016002255A1 - Inhibidores de c5a para el tratamiento de la neumonía viral - Google Patents

Inhibidores de c5a para el tratamiento de la neumonía viral

Info

Publication number: CL2016002255A1
Authority: CL; Chile
Prior art keywords: inhibitors; treatment; viral pneumonia; pneumonia; viral
Prior art date: 2014-03-20

Application number

CL2016002255A

Other languages

English (en)

Inventor

Renfeng Guo

Niels Christoph Riedemann

Original Assignee

Inflarx Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-03-20

Filing date

2016-09-06

Publication date

2017-08-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50342223&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016002255(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-09-06 Application filed by Inflarx Gmbh filed Critical Inflarx Gmbh

2017-08-25 Publication of CL2016002255A1 publication Critical patent/CL2016002255A1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Zoology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Mycology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Oncology (AREA)
Pulmonology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CL2016002255A 2014-03-20 2016-09-06 Inhibidores de c5a para el tratamiento de la neumonía viral CL2016002255A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP14160947		2014-03-20

Publications (1)

Publication Number	Publication Date
CL2016002255A1 true CL2016002255A1 (es)	2017-08-25

Family

ID=50342223

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2016002255A CL2016002255A1 (es)	2014-03-20	2016-09-06	Inhibidores de c5a para el tratamiento de la neumonía viral

Country Status (15)

Country	Link
US (2)	US10227397B2 (es)
EP (1)	EP3119802B1 (es)
JP (2)	JP6718379B2 (es)
KR (1)	KR20160127042A (es)
CN (2)	CN116785426A (es)
AU (1)	AU2015233380A1 (es)
BR (1)	BR112016021629A2 (es)
CA (1)	CA2940319A1 (es)
CL (1)	CL2016002255A1 (es)
EA (1)	EA201691481A1 (es)
IL (1)	IL247364A0 (es)
MX (1)	MX2016011862A (es)
PH (1)	PH12016501830A1 (es)
SG (1)	SG11201607740TA (es)
WO (1)	WO2015140304A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20170127A1 (es)	2014-03-20	2017-03-30	Samumed Llc	Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas
BR112016021629A2 (pt)	2014-03-20	2018-07-10	Inflarx Gmbh	inibidores de c5a para o tratamento de pneumonia viral
KR102503319B1 (ko)	2014-06-12	2023-02-28	라 파마슈티컬스 인코포레이티드	보체 활성의 조절
US9937222B2 (en)	2015-01-28	2018-04-10	Ra Pharmaceuticals, Inc.	Modulators of complement activity
RS64067B1 (sr)	2015-12-16	2023-04-28	Ra Pharmaceuticals Inc	Modulatori aktivnosti komplementa
US20190127453A1 (en)	2016-06-07	2019-05-02	Novartis Ag	An anti-c5 antibody dosing regimen
SG10202012243VA (en)	2016-06-14	2021-01-28	Regeneron Pharma	Anti-c5 antibodies and uses thereof
WO2018106859A1 (en)	2016-12-07	2018-06-14	Ra Pharmaceuticals, Inc.	Modulators of complement activity
US10376595B2 (en)	2017-04-03	2019-08-13	Inflarx Gmbh	Treatment of inflammatory diseases with inhibitors of C5a activity
EP3411400B1 (en)	2017-04-03	2021-09-22	InflaRx GmbH	Treatment of inflammatory diseases with inhibitors of c5a activity
JP7502865B2 (ja) *	2017-06-23	2024-06-19	インフラルクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	Ｃ５ａ活性のインヒビターでの炎症性疾患の処置
AU2018383751B2 (en)	2017-12-13	2025-05-08	Regeneron Pharmaceuticals, Inc.	Anti-C5 antibody combinations and uses thereof
BR112022002831A2 (pt)	2019-08-16	2022-06-28	Regeneron Pharma	Formulações anti-c5 de alta concentração
TWI867422B (zh) *	2020-03-06	2024-12-21	美商奥默羅斯公司	用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法
CA3172421A1 (en) *	2020-03-27	2021-09-30	Niels C. Riedemann	Inhibitors of c5a for the treatment of corona virus infection
US20230416344A1 (en) *	2020-04-16	2023-12-28	Alexion Pharmaceuticals, Inc.	Methods for treating a complement mediated disorder caused by viruses
TW202208427A (zh) *	2020-05-06	2022-03-01	德商因夫萊亞斯有限公司	人源化抗ｃ５ａ抗體
US20240415980A1 (en)	2021-10-28	2024-12-19	Regeneron Pharmaceuticals, Inc.	Crispr/cas-related methods and compositions for knocking out c5
US12180274B2 (en) *	2023-05-26	2024-12-31	Inflarx Gmbh	Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7432356B2 (en) *	2001-08-17	2008-10-07	Genentech, Inc.	Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
EP2371861B1 (en) *	2002-01-25	2017-08-09	Novo Nordisk A/S	Monoclonal antibodies against extracellular loops of C5aR
EP2327725A1 (en)	2009-11-26	2011-06-01	InflaRx GmbH	Anti-C5a binding moieties with high blocking activity
PL2521562T3 (pl) *	2010-01-08	2020-04-30	Volution Immuno Pharmaceuticals Sa	Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych
PT2563813E (pt) *	2010-04-30	2015-11-26	Alexion Pharma Inc	Anticorpos anti-c5a e métodos para utilização dos anticorpos
CA2839421C (en) *	2010-06-17	2019-12-03	Trellis Bioscience, Llc	Antibodies useful in passive influenza immunization
BR112016021629A2 (pt)	2014-03-20	2018-07-10	Inflarx Gmbh	inibidores de c5a para o tratamento de pneumonia viral

2015
- 2015-03-20 BR BR112016021629A patent/BR112016021629A2/pt not_active Application Discontinuation
- 2015-03-20 AU AU2015233380A patent/AU2015233380A1/en not_active Abandoned
- 2015-03-20 CN CN202310453303.8A patent/CN116785426A/zh active Pending
- 2015-03-20 KR KR1020167025906A patent/KR20160127042A/ko not_active Ceased
- 2015-03-20 JP JP2016558056A patent/JP6718379B2/ja active Active
- 2015-03-20 EA EA201691481A patent/EA201691481A1/ru unknown
- 2015-03-20 CA CA2940319A patent/CA2940319A1/en not_active Abandoned
- 2015-03-20 EP EP15711177.4A patent/EP3119802B1/en active Active
- 2015-03-20 WO PCT/EP2015/055947 patent/WO2015140304A1/en not_active Ceased
- 2015-03-20 MX MX2016011862A patent/MX2016011862A/es unknown
- 2015-03-20 SG SG11201607740TA patent/SG11201607740TA/en unknown
- 2015-03-20 US US15/127,676 patent/US10227397B2/en active Active
- 2015-03-20 CN CN201580014552.0A patent/CN106132982A/zh active Pending
2016
- 2016-08-18 IL IL247364A patent/IL247364A0/en unknown
- 2016-09-06 CL CL2016002255A patent/CL2016002255A1/es unknown
- 2016-09-19 PH PH12016501830A patent/PH12016501830A1/en unknown
2019
- 2019-01-24 US US16/256,100 patent/US10858421B2/en active Active
2020
- 2020-04-16 JP JP2020073194A patent/JP7041708B2/ja active Active

Also Published As

Publication number	Publication date
MX2016011862A (es)	2016-12-05
JP6718379B2 (ja)	2020-07-08
JP2020125324A (ja)	2020-08-20
JP2017514791A (ja)	2017-06-08
EA201691481A1 (ru)	2017-02-28
IL247364A0 (en)	2016-11-30
JP7041708B2 (ja)	2022-03-24
US10227397B2 (en)	2019-03-12
SG11201607740TA (en)	2016-10-28
EP3119802A1 (en)	2017-01-25
US20190202900A1 (en)	2019-07-04
CN106132982A (zh)	2016-11-16
WO2015140304A1 (en)	2015-09-24
CN116785426A (zh)	2023-09-22
US20170137499A1 (en)	2017-05-18
CA2940319A1 (en)	2015-09-24
PH12016501830A1 (en)	2016-11-21
BR112016021629A2 (pt)	2018-07-10
AU2015233380A1 (en)	2016-09-08
EP3119802B1 (en)	2019-12-04
KR20160127042A (ko)	2016-11-02
US10858421B2 (en)	2020-12-08

Publication	Publication Date	Title
CL2016002255A1 (es)	2017-08-25	Inhibidores de c5a para el tratamiento de la neumonía viral
DK3132036T3 (da)	2020-03-16	Målrettede mutationer
HUE042335T2 (hu)	2019-06-28	ROR-gamma dihidropirrolopiridin inhibitorai
IL248661A0 (en)	2017-01-31	5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
BR112016021682A2 (pt)	2018-06-26	cenicriviroc para o tratamento da fibrose
PL3166834T3 (pl)	2020-10-19	Układy stacji napędowych
SG11201609652RA (en)	2016-12-29	Treatment of polybacterials infections
BR112016022976A2 (pt)	2017-08-15	Métodos para o tratamento de hcv
DK3132009T3 (da)	2023-02-06	Fremgangsmåde
DK3186242T3 (da)	2021-12-20	Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3283210T3 (da)	2021-11-22	Fremgangsmåde
DK3114120T3 (da)	2019-05-20	Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
LT3212237T (lt)	2022-02-25	Metotreksato vaistinė forma
HUE049170T2 (hu)	2020-09-28	Eljárás szubsztituált cikloszerinek elõállítására
FR3023290B1 (fr)	2016-08-19	Derives de flavaglines
HUE042043T2 (hu)	2019-06-28	Malária megelõzésére vagy kezelésére alkalmas triaminopiridin-vegyületek
IL254502B (en)	2020-09-30	Solid forms of menaquinols
GB201404552D0 (en)	2014-04-30	Purification of dna-conjugate products
IL248608A0 (en)	2016-12-29	Heparan sulphates
DK3205661T3 (da)	2021-08-02	Hsp70-afledt immunitetsinducerende peptid
FR3024647B1 (fr)	2017-02-17	Transat de puericulture
EP3217965C0 (en)	2024-04-24	Pharmaceutical processing
IL247553B (en)	2020-06-30	Transportation of medical instruments
DK3285588T3 (da)	2019-07-08	Fremgangsmåde
PT3139932T (pt)	2018-11-14	Regime de tratamento para composto de tiacumicina